Observational studyCurrent neuropharmacology2026
Blockade of Interleukin-6 Receptor with Tocilizumab During the Acute Phase of Childhood Immune-Mediated Epilepsy can Lead to a Favorable Outcome - an Observational Study.
Observational study in Current neuropharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionTo explore the role of tocilizumab in treating childhood immune-mediated epilepsy and determine the role of interleukin-6 (IL-6) in its pathogenesis.
methodsWe collected and analyzed clinical information of pediatric patients diagnosed with immune- mediated epilepsy and treated with tocilizumab at Xiangya Hospital.
resultsThis study included four males with a median age of onset of 4.3 years. They presented with seizures, fever, and neuropsychiatric manifestations. A combination of different anti-seizure medications (ASMs) and first-line immunotherapy could not control seizures. All patients had elevated levels of IL-6 in their serum and/or cerebrospinal fluid at some points. The median time from disease onset to the first dose of tocilizumab was 25 days. Patients 2 and 3 received tocilizumab in the acute phase of the disease, but patients 1 and 4 received this therapy in the subacute phase. At the last follow-up, patients 2 and 3 had no seizures, while patients 1 and 4 still had chronic epilepsy, but with > 50% reduction of seizure frequency. All patients regained normal cognition. DISCUSSION: IL-6 may play a role in the pathogenesis of immune-mediated epilepsy, and introducing tocilizumab in the acute phase might be effective in preventing the disease from progressing into the chronic phase.
conclusionTocilizumab is effective for the management of immune-mediated epilepsy in children when given early enough.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.